Summary – The standard diagnostic method for breast implant infection—culturing periprosthetic fluid— while highly accurate, is time-consuming, often requiring an average of 4-5 days to produce results. This delay can be critical, as timely intervention is paramount to preventing the escalation of infection and minimizing patient morbidity. This need for speed and precision is what led us to explore the use of a commercially available multiplex-PCR assay: it is an in vitro diagnostic assay which detects 31 bacterial and yeast nucleic acids and selects eight antimicrobial resistance genes most involved in joint infections. Here we present a new protocol to evaluate the effectiveness of the JI Panel in diagnosing breast implant infections. The study included 15 consecutive patients, who presented with clinical signs of infection following breast implant surgery. Each patient underwent both the traditional periprosthetic fluid culture and the JI Panel molecular diagnostic test. Out of the 15 patients tested, 14 cases showed complete concordance between the results obtained from the JI Panel and those from traditional cultures. By providing rapid, accurate diagnostic results, this technology enables surgeons to make informed decisions about patient care much sooner than was previously possible. This innovation has the potential to not only become a new standard of care in managing implant-associated infections but also to be expanded into other areas of plastic surgery where rapid diagnosis is critical. All patients gave consent for their medical information to be published in print and online with the understanding that this information may be publicly available.
“Rapid Molecular Diagnosis of Breast Implant Infections: A New Frontier in Plastic Surgery”
Vizzielli G.;
2025-01-01
Abstract
Summary – The standard diagnostic method for breast implant infection—culturing periprosthetic fluid— while highly accurate, is time-consuming, often requiring an average of 4-5 days to produce results. This delay can be critical, as timely intervention is paramount to preventing the escalation of infection and minimizing patient morbidity. This need for speed and precision is what led us to explore the use of a commercially available multiplex-PCR assay: it is an in vitro diagnostic assay which detects 31 bacterial and yeast nucleic acids and selects eight antimicrobial resistance genes most involved in joint infections. Here we present a new protocol to evaluate the effectiveness of the JI Panel in diagnosing breast implant infections. The study included 15 consecutive patients, who presented with clinical signs of infection following breast implant surgery. Each patient underwent both the traditional periprosthetic fluid culture and the JI Panel molecular diagnostic test. Out of the 15 patients tested, 14 cases showed complete concordance between the results obtained from the JI Panel and those from traditional cultures. By providing rapid, accurate diagnostic results, this technology enables surgeons to make informed decisions about patient care much sooner than was previously possible. This innovation has the potential to not only become a new standard of care in managing implant-associated infections but also to be expanded into other areas of plastic surgery where rapid diagnosis is critical. All patients gave consent for their medical information to be published in print and online with the understanding that this information may be publicly available.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.


